{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:36:43Z","timestamp":1772825803867,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007291","name":"SUVA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40273-023-01305-3","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T06:01:47Z","timestamp":1691820107000},"page":"1641-1655","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2682-537X","authenticated-orcid":false,"given":"Michaela Carla","family":"Barbier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Fengler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Bhadhuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklaus","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Gautschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,12]]},"reference":[{"key":"1305_CR1","unstructured":"NICE. Final appraisal document (FAD). Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma. 2022; https:\/\/www.nice.org.uk\/guidance\/ta818\/documents\/html-content-4."},{"key":"1305_CR2","unstructured":"NICE. Committee papers 2021. Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]. 2021; https:\/\/www.nice.org.uk\/guidance\/ta818\/evidence."},{"issue":"142","key":"1305_CR3","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1183\/16000617.0063-2016","volume":"25","author":"AC Bibby","year":"2016","unstructured":"Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev. 2016;25(142):472\u201386.","journal-title":"Eur Respir Rev"},{"issue":"3","key":"1305_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/1078-0432.CCR-21-1466","volume":"28","author":"EC Nakajima","year":"2022","unstructured":"Nakajima EC, Vellanki PJ, Larkins E, Chatterjee S, Mishra-Kalyani PS, Bi Y, et al. FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res. 2022;28(3):446\u201351.","journal-title":"Clin Cancer Res"},{"issue":"10272","key":"1305_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375\u201386.","journal-title":"Lancet"},{"key":"1305_CR6","unstructured":"CANCER TODAY International Agency for Research on Cancer. GLOBOCAN 2020 Fact Sheet Mesothelioma. https:\/\/gco.iarc.fr\/today\/fact-sheets-cancers."},{"key":"1305_CR7","unstructured":"Suva. Unfallstatistik UVG 2020. 2020; https:\/\/www.unfallstatistik.ch\/d\/publik\/unfstat\/unfstat_d.htm."},{"issue":"1","key":"1305_CR8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s12885-022-09750-7","volume":"22","author":"A Moore","year":"2022","unstructured":"Moore A, Bennett B, Taylor-Stokes G, McDonald L, Daumont MJ. Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe. BMC Cancer. 2022;22(1):693.","journal-title":"BMC Cancer"},{"key":"1305_CR9","unstructured":"Cancer Research UK. Mesothelioma statistics. 2020. https:\/\/www.cancerresearchuk.org\/about-cancer\/mesothelioma\/survival."},{"key":"1305_CR10","unstructured":"National Comprehensive Cancer Network\u00a9. NCCN Clinical Practice Guidelines in Oncology, Malignant Pleural Mesothelioma. Version 1.2022. 2022; https:\/\/www.nccn.org\/home."},{"issue":"2","key":"1305_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","volume":"33","author":"S Popat","year":"2022","unstructured":"Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson A, Nowak A, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2022;33(2):129\u201342.","journal-title":"Ann Oncol"},{"issue":"10026","key":"1305_CR12","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. The Lancet. 2016;387(10026):1405\u201314.","journal-title":"The Lancet"},{"issue":"5","key":"1305_CR13","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488\u201399.","journal-title":"Ann Oncol"},{"key":"1305_CR14","unstructured":"NICE. Committee Papers 2022. Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]. 2022; https:\/\/www.nice.org.uk\/guidance\/ta818\/documents\/html-content-4."},{"key":"1305_CR15","doi-asserted-by":"publisher","first-page":"S1438","DOI":"10.1016\/j.annonc.2022.08.077","volume":"33","author":"G Zalcman","year":"2022","unstructured":"Zalcman G, Oulkhouir Y, Cornelissen R, Greillier L, Cid JR, Mazieres J, et al. LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743. Ann Oncol. 2022;33:S1438\u20139.","journal-title":"Ann Oncol"},{"key":"1305_CR16","unstructured":"CADTH. CADTH Reimbursement Recommendation Nivolumab In Combination With Ipilimumab (Opdivo-Yervoy). 2021; https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2021\/PC0229%20Opdivo-Yervoy%20%20Final%20Rec.pdf."},{"key":"1305_CR17","unstructured":"IQWiG. Nivolumab (malignes Pleuramesotheliom)\u2014Nutzenbewertung Bericht Nr. 1209. 2021; https:\/\/www.iqwig.de\/download\/a21-89_nivolumab_nutzenbewertung-35a-sgb-v_v1-0.pdf."},{"key":"1305_CR18","unstructured":"Organisation for Economic Co-operation and Development (OECD). Health spending USD per capita. https:\/\/data.oecd.org\/healthres\/health-spending.htm."},{"key":"1305_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.947375","volume":"10","author":"ZM Ye","year":"2022","unstructured":"Ye ZM, Tang ZQ, Xu Z, Zhou Q, Li H. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma. Front Public Health. 2022;10: 947375.","journal-title":"Front Public Health"},{"key":"1305_CR20","doi-asserted-by":"publisher","first-page":"175883592211166","DOI":"10.1177\/17588359221116604","volume":"14","author":"L Yang","year":"2022","unstructured":"Yang L, Cao X, Li N, Zheng B, Liu M, Cai H. Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma. Ther Adv Med Oncol. 2022;14:17588359221116604.","journal-title":"Ther Adv Med Oncol."},{"issue":"3","key":"1305_CR21","doi-asserted-by":"publisher","first-page":"A153","DOI":"10.1016\/j.jval.2016.03.1610","volume":"19","author":"J Malacan","year":"2016","unstructured":"Malacan J, Carlson J. Cost-effectiveness analysis of addition of bevacizumab to a standard chemotherapy doublet (pemetrexed+ cisplatin) in patients with malignant pleural mesothelioma. Value in Health. 2016;19(3):A153.","journal-title":"Value in Health."},{"key":"1305_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.05.012","volume":"110","author":"M Zhan","year":"2017","unstructured":"Zhan M, Zheng H, Xu T, Yang Y, Li Q. Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial. Lung Cancer. 2017;110:1\u20136.","journal-title":"Lung Cancer"},{"issue":"1","key":"1305_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12962-019-0182-7","volume":"17","author":"MA Pahuta","year":"2019","unstructured":"Pahuta MA, Werier J, Wai EK, Patchell RA, Coyle D. A technique for approximating transition rates from published survival analyses. Cost Effectiveness Resource Allocation. 2019;17(1):12.","journal-title":"Cost Effectiveness Resource Allocation."},{"key":"1305_CR24","unstructured":"TreeAge LLC. TreeAge User Manual. https:\/\/www.treeage.com\/support\/electronic-help\/."},{"issue":"7","key":"1305_CR25","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","volume":"3","author":"A Santoro","year":"2008","unstructured":"Santoro A, O\u2019Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008;3(7):756\u201363.","journal-title":"J Thorac Oncol"},{"issue":"Suppl 2","key":"1305_CR26","doi-asserted-by":"publisher","first-page":"S304","DOI":"10.21037\/jtd.2017.10.19","volume":"10","author":"M Cinausero","year":"2018","unstructured":"Cinausero M, Rihawi K, Sperandi F, Melotti B, Ardizzoni A. Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. J Thorac Dis. 2018;10(Suppl 2):S304\u201310.","journal-title":"J Thorac Dis"},{"issue":"14_suppl","key":"1305_CR27","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.1200\/jco.2004.22.90140.7021","volume":"22","author":"JPV Meerbeeck","year":"2004","unstructured":"Meerbeeck JPV, Manegold C, Gaafar R, Klaveren RJV, Marck EAV, Vincent M, et al. A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC. J Clin Oncol. 2004;22(14_suppl):7021.","journal-title":"J Clin Oncol"},{"key":"1305_CR28","unstructured":"Exchange Rates UK. Swiss Franc to US Dollar Spot Exchange Rates for 2022. https:\/\/www.exchangerates.org.uk\/CHF-USD-spot-exchange-rates-history-2022.html."},{"issue":"11","key":"1305_CR29","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.jtho.2016.05.032","volume":"11","author":"K Matter-Walstra","year":"2016","unstructured":"Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, et al. A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous NSCLC including PD-L1 testing. J Thorac Oncol. 2016;11(11):1846\u201355.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"1305_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277282","volume":"17","author":"MC Barbier","year":"2022","unstructured":"Barbier MC, Tomonaga Y, Menges D, Yebyo HG, Haile SR, Puhan MA, et al. Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer. PLoS ONE. 2022;17(11): e0277282.","journal-title":"PLoS ONE"},{"key":"1305_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10198-021-01398-7","volume":"23","author":"M Barbier","year":"2022","unstructured":"Barbier M, Durno N, Bennison C, \u00d6rtli M, Knapp C, Schwenkglenks M. Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed\/refractory chronic lymphocytic leukemia in Switzerland. Eur J Health Econ. 2022;23:1\u201310.","journal-title":"Eur J Health Econ"},{"key":"1305_CR32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s10198-021-01282-4","volume":"22","author":"MC Barbier","year":"2021","unstructured":"Barbier MC, Pardo E, Panje CM, Gautschi O, Lupatsch JE, Research SGfCC. A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland. Eur J Health Econ. 2021;22:669\u201377.","journal-title":"Eur J Health Econ"},{"key":"1305_CR33","volume":"149","author":"A Bhadhuri","year":"2019","unstructured":"Bhadhuri A, Insinga R, Guggisberg P, Panje C, Schwenkglenks M. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. Swiss Med Wkly. 2019;149: w20170.","journal-title":"Swiss Med Wkly"},{"issue":"4","key":"1305_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266934","volume":"17","author":"H Iino","year":"2022","unstructured":"Iino H, Hashiguchi M, Hori S. Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: a systematic review. PLoS ONE. 2022;17(4): e0266934.","journal-title":"PLoS ONE"},{"key":"1305_CR35","unstructured":"Swiss Federal Statistical Office. Gross domestic product per capita. 23.11.2022]; https:\/\/www.bfs.admin.ch\/bfs\/en\/home\/statistics\/national-economy\/national-accounts\/gross-domestic-product.assetdetail.23184194.html."},{"issue":"5","key":"1305_CR36","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","volume":"36","author":"P Thokala","year":"2018","unstructured":"Thokala P, Ochalek J, Leech AA, Tong T. Cost-effectiveness thresholds: the past, the present and the future. Pharmacoeconomics. 2018;36(5):509\u201322.","journal-title":"Pharmacoeconomics"},{"key":"1305_CR37","unstructured":"DigitizeIt. DigitizeIt software. https:\/\/www.digitizeit.xyz\/."},{"key":"1305_CR38","unstructured":"R software. https:\/\/www.r-project.org\/."},{"key":"1305_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"1305_CR40","unstructured":"Federal Office of Public Health. Swiss Specialty List (\"Schweizer Spezialit\u00e4tenliste\"). http:\/\/www.spezialitaetenliste.ch\/ShowPreparations.aspx?searchType=SUBSTANCE."},{"key":"1305_CR41","unstructured":"Swiss Federal Statistical Office. Mean body height (in cm). https:\/\/www.bfs.admin.ch\/bfs\/de\/home\/statistiken\/gesundheit.assetdetail.7586022.html."},{"key":"1305_CR42","unstructured":"Swiss Federal Statistical Office. Mean body weight (in cm). https:\/\/www.bfs.admin.ch\/bfs\/de\/home\/statistiken\/gesundheit.assetdetail.7586025.html."},{"key":"1305_CR43","unstructured":"Online Definitionshandbuch SwissDRG 9.0. 16.11.2022]; https:\/\/manual.swissdrg.org\/de\/11.3\/supplements."},{"key":"1305_CR44","unstructured":"TARMED Online Browser Tarifversion 1.09. 1.2.2021]; https:\/\/www.tarmed-browser.ch\/de."},{"key":"1305_CR45","unstructured":"Analysenliste (Version 1.August 2022). Swiss Federal Office of Public Health. 2022; https:\/\/www.bag.admin.ch\/bag\/de\/home\/versicherungen\/krankenversicherung\/krankenversicherung-leistungen-tarife\/Analysenliste.html."},{"key":"1305_CR46","unstructured":"Swiss Federal Statistical Office. Population size and change in Switzerland in 2021: definitive figures. https:\/\/www.bfs.admin.ch\/bfs\/en\/home\/statistics\/population.gnpdetail.2022-0467.html."},{"key":"1305_CR47","unstructured":"Swiss Federal Statistical Office. Key population figures, 1950-2021. https:\/\/www.bfs.admin.ch\/bfs\/en\/home\/statistics\/population.assetdetail.23328853.html."},{"key":"1305_CR48","unstructured":"National Institute for Cancer Epidemiology and Registration (NICER). https:\/\/www.nicer.org\/en\/home."},{"issue":"3","key":"1305_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121071","volume":"10","author":"S Cedr\u00e9s","year":"2015","unstructured":"Cedr\u00e9s S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE. 2015;10(3): e0121071.","journal-title":"PLoS ONE"},{"key":"1305_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100050","volume":"3","author":"DL Carl","year":"2021","unstructured":"Carl DL, Vokinger KN. Patients\u2019 access to drugs with rebates in Switzerland\u2014empirical analysis and policy implications for drug pricing in Europe. Lancet Regional Health - Europe. 2021;3: 100050.","journal-title":"Lancet Regional Health - Europe."},{"key":"1305_CR51","unstructured":"Exchange Rates UK. Swiss Franc to Canadian Dollar Spot Exchange Rates for 2021. https:\/\/www.exchangerates.org.uk\/CAD-CHF-spot-exchange-rates-history-2021.html."},{"issue":"11","key":"1305_CR52","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","volume":"13","author":"Y Metaxas","year":"2018","unstructured":"Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, et al. Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. J Thorac Oncol. 2018;13(11):1784\u201391.","journal-title":"J Thorac Oncol"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01305-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-023-01305-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01305-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T14:15:21Z","timestamp":1699539321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-023-01305-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,12]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1305"],"URL":"https:\/\/doi.org\/10.1007\/s40273-023-01305-3","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,12]]},"assertion":[{"value":"18 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by University of Basel. This work was funded by the Swiss Institute for Accident Insurance (Suva). Neither the study funder, nor the manufacturer of nivolumab and ipilimumab, were involved in determining the research question, the study design, data collection, analysis, interpretation, decision to publish, or writing of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Unrelated to the submitted work, MB has received personal fees from Vifor for participation in an advisory board meeting. OG attended advisory boards by Eli Lilly, was consultant for Amgen, and is member of a data safety monitoring board for Boehringer Ingelheim (all honoraria were paid to his institution). AB, AF, EP, and NM have declared no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\/competing interests"}},{"value":"We requested approval from the Ethics Committee Northwest and Central Switzerland for the use of aggregate resource use and cost data of patients treated at the Cantonal Hospital of Lucerne from 2011 to 2022. According to our request (Req-2022-00420), ethical approval was not needed for the use of anonymized and aggregated data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The parameter values used in this model are included in the published article (and its supplementary information files) or are available from the corresponding author on reasonable request for non-commercial purposes. Access to underlying data from the National Institute for Cancer Epidemiology and Registration and the Cantonal Hospital of Lucerne is possible via the data owners following their regulations. Where relevant, contact can be established with the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The cost-effectiveness model was implemented in TreeAge and is available from the corresponding author (MB) on reasonable request for non-commercial purpose.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MB, AF, and OG conceived and designed the study. MB performed the survival modelling in R, developed and implemented the model in TreeAge, and performed the model validation. AF, OG, and EP provided aggregate resource use and cost data of medical records of patients from the Cantonal Hospital of Lucerne. MB drafted the grant application and the manuscript. AB and NM helped with the resubmission and performed a detailed review of the manuscript. All authors reviewed and commented on the manuscript for important intellectual content and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}